Cipla posts record revenue, strengthens chronic care portfolio

Cipla Limited announced an all-time high quarterly revenue of INR7,589 crores for Q2 FY26, marking an 8% year-on-year growth with a robust EBITDA margin of 25%. The company's One-India business showed a 7% year-on-year increase, with key therapies like anti-diabetes (+10%), cardiac (+13%), urology (+17%), and dermatology (+18%) demonstrating strong double-digit growth. Cipla also entered the obesity care segment with the launch of Yurpeak (tirzepatide) in partnership with Eli Lilly.

North America contributed $233m in quarterly revenue, with Cipla becoming the number one player in the U.S. albuterol MDI market, achieving a 22% market share. The EMEU business recorded its strongest quarterly revenue to date at $110m, a 15% year-on-year growth. The company reported a profit after tax of INR1,351 crores, representing 17.8% of sales, with R&D investments reaching INR539 crores (7.1% of revenue).

Cipla anticipates a significantly lower contribution from generic Revlimid in Q3 FY26. For calendar year 2026, the company expects to launch four major respiratory assets, including generic Advair, and three peptide assets, including liraglutide, with many filings from U.S. facilities. The full-year EBITDA margin guidance has been revised to 22.75% to 24%, excluding the Yurpeak business plan.